Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler
News
DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
Until now, SGLT2 inhibitors were for patients with an eGFR of at least 30 mL/min per m2. New evidence moves the threshold down to 25....
News
VERTIS CV: Ertugliflozin’s proven benefits fall short of other SGLT2 inhibitors
Added analyses from ertugliflozin’s cardiovascular outcome trial hint at SGLT2 inhibitor–consistent benefits, but proven benefits remain scant.
News
Survival after kidney transplantation lags in diabetes patients
Overall U.S. survival after kidney transplantation rose during 2000-2018, but less so in patients with type 1 or type 2 diabetes.
News
‘Dose response’ between exercise and improvement in diabetes
As adherence to a thrice-weekly, supervised exercise class rose, A1c levels fell. Aerobic exercise, or a combination of aerobic and resistance...
News
IMPACT-AFib: Single mailing fails to budge oral anticoagulant uptake for AFib
Researchers examined whether a minimal intervention – a single educational mailing – could boost oral anticoagulant use among AFib patients. It...
News
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
DAPA-CKD showed that dapagliflozin helps patients with albuminuria and declining eGFR levels whether or not they have type 2 diabetes.
News
Cleaner data confirm severe COVID-19 link to diabetes, hypertension
Initial reports that tied more severe COVID-19 disease to diabetes or hypertension used confounded data, but more refined data show similar links...
News
Terlipressin squeaks by FDA review for hepatorenal syndrome 1
The FDA advisory committee’s 8-7 vote favoring approval of terlipressin for hepatorenal syndrome type 1 reflected concerns and misgivings.
News
SGLT2 inhibitors, developed for T2D, now ‘belong to cardiologists and nephrologists’
When the SGT2 inhibitor drugs first came to the U.S. market they were labeled for just treating hyperglycemia, but those days are over.
News
Dropping race-based eGFR adjustment gains traction in U.S.
“Race is a social, not a biological, construct and the kidney-function race multiplier ignores the substantial genetic diversity within self-...